Title

Neuropathic pain: preclinical and early clinical progress with voltage-gated sodium channel blockers

Affiliations

Department of Anesthesiology, Advocate Illinois Masonic Medical Center

Department of Anesthesiology, Advocate Illinois Masonic Medical Center

Department of Anesthesiology, Advocate Illinois Masonic Medical Center

Department of Anesthesiology, Advocate Illinois Masonic Medical Center

Abstract

Introduction: Neuropathic pain is a chronic condition that significantly affects the quality of life of millions of people globally. Most of the pharmacologic treatments currently in use demonstrate modest efficacy and over half of all patients do not respond to medical management. Hence, there is a need for new, efficacious drugs. Evidence points toward voltage-gated sodium channels as a key target for novel analgesics.

Area covered: The role of voltage-gated sodium channels in pain pathophysiology is illuminated and the preclinical and clinical data for new sodium channel blockers and toxin-derived lead compounds are examined. The expansion of approved sodium channel blockers is discussed along with the limitations of current research, trends in drug development, and the potential of personalized medicine.

Expert opinion: The transition from preclinical to clinical studies can be difficult because of the inherent inability of animal models to express the complexities of pain states. Pain pathways are notoriously intricate and may be pharmacologically modulated at a variety of targets; it is unlikely that action at a single target could completely abolish a pain response because pain is rarely unifactorial. Combination therapy may be necessary and this could further confound the discovery of novel agents.

Document Type

Article

PubMed ID

32070160

Link to Full Text

 

Share

COinS